Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2019Annual Review of Medicine

CD40 Agonist Antibodies in Cancer Immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RVRobert H. Vonderheide

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Robert H. Vonderheide (2019) studied this question.

synapsesocial.com/papers/69d78d00ef4aa71f97f319eahttps://doi.org/10.1146/annurev-med-062518-045435
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer2016 · 294 citations
  2. 2The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity2014 · 103 citations
  3. 3CD40 stimulation leads to effective therapy of CD40<sup>−</sup>tumors through induction of strong systemic cytotoxic T lymphocyte immunity2002 · 224 citations
  4. 4Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma2014 · 44 citations
  5. 5CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy2016 · 64 citations